VPA22033/040/001

Cronyxin Injection 50 mg/ml Solution for Injection

Variation	Summary	Date
Vet - G.I.2 b)	VRA-S - Vet - G.I.2 b) - b) Harmonisation of the generic/hybrid product according to article 71(1) after SPC harmonisation of the reference product - G.I.2 b) Safety, Efficacy, Pharmacovigilance changes - Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid medicinal product following assessment of the same change for the reference product - Harmonisation of the generic/hybrid product according to article 71(1) after SPC harmonisation of the reference product	01/05/25
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	01/05/25
Vet - F.II.b.2 b) z.	VRA-R - Vet - F.II.b.2 b) z b) Replacement or addition of a manufacturer responsible for importation and/or batch release z. Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.b.2 b) z.	12/07/23
Vet - F.II.b.3 a)	VRA-R - Vet - F.II.b.3 a) - a) Minor change in the manufacturing process - F.II.b.3 a) Quality Changes - Finished Product -Manufacture - Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - Minor change in the manufacturing process	12/07/23
Vet - F.II.b.1 d)	VRA-R - Vet - F.II.b.1 d) - d) Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile veterianry medicinal	12/07/23

		T
	products (including those that are aseptically manufactured) excluding biological/immunological veterinary medicinal	
	products - F.II.b.1 d) Quality Changes - Finished Product	
	1.5	
	-Manufacture - Replacement or addition of a manufacturing	
	site for part or all of the manufacturing process of the finished	
	product - Site where any manufacturing operation(s) take	
	place, except batch release, batch control, and secondary	
	packaging, for sterile veterianry medicinal products (including	
	those that are aseptically manufactured) excluding biological/	
	immunological veterinary medicinal products	
	VNRA - Vet - B3 t) - t) Deletion of a Ph. Eur. CEP - B3 t)	
	Changes to the quality part of the dossier: Deletion of a Ph.	
Vet - B3 t)	Eur. CEP — for an active substance; — for a starting material,	07/07/23
	reagent or intermediate used in the manufacturing process of	
	the active substance; — for an excipient	
	VNRA - Vet - B44 - Submission of a new or updated Ph. Eur.	
	CEP from an already approved manufacturer for a non-sterile	
	active substance, starting material, reagent or intermediate,	
Vet - B44	excipient - B44 Changes to the quality part of the dossier:	07/07/23
	Submission of a new or updated Ph. Eur. CEP from an already	
	approved manufacturer for a non-sterile: — active substance;	
	— starting material, reagent or intermediate used in the	
	manufacturing process of the active substance; — excipient	
	VNRA - Vet - B44 - Submission of a new or updated Ph. Eur.	
	CEP from an already approved manufacturer for a non-sterile	
	active substance, starting material, reagent or intermediate,	
77 . 79.44	excipient - B44 Changes to the quality part of the dossier:	07/07/00
Vet - B44	Submission of a new or updated Ph. Eur. CEP from an already	07/07/23
	approved manufacturer for a non-sterile: — active substance;	
	— starting material, reagent or intermediate used in the	
	manufacturing process of the active substance; — excipient	
	VNRA - Vet - B21 - Replacement or addition of a secondary	
	packaging site of a finished product - B21 Changes to the	
Vet - B21		07/07/23
	quality part of the dossier: Replacement or addition of a	
	secondary packaging site of a finished product	
	VNRA - Vet - C4 - Change(s) in the SPC, labelling or package	
	leaflet intended to implement the outcome of a procedure or	
	recommendation from the competent authority or the Agency	
	concerning risk management measures in pharmacovigilance	
Vet - C4	related to veterinary medicinal products - C4 Changes to the	
	safety, efficacy and pharmacovigilance part of the dossier:	05/04/23
	Change(s) in the SPC, labelling or package leaflet intended to	
	implement the outcome of a procedure or recommendation	
	from the competent authority or the Agency concerning risk	
	management measures in pharmacovigilance related to	
	veterinary medicinal products	
	VRA-S - Vet - G.I.18 - One-off alignment of the product	
	information with version 9.0 (or the latest version of the QRD	
Vet - G.I.18	templates that are in effect at the time that this one-off	14/12/22
	variation is submitted) of the QRD templates i.e. major update	
	variation is submitted) of the QKD templates i.e. major update	

		1
	of the QRD templates in accordance with Regulation (EU)	
	2019/6, for veterinary medicinal products placed on the	
	market in accordance with Directive 2001/82/EC or	
	Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy,	
	Pharmacovigilance changes - One-off alignment of the	
	product information with version 9.0 (or the latest version of	
	the QRD templates that are in effect at the time that this	
	one-off variation is submitted) of the QRD templates i.e.	
	major update of the QRD templates in accordance with	
	Regulation (EU) 2019/6, for veterinary medicinal products	
	placed on the market in accordance with Directive	
	2001/82/EC or Regulation (EC) No 726/2004	
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or	
	changes to the summary of the PSMF not already covered	
	elsewhere in the Annex to Regulation (EU) 2021/17 - C6	
	Changes to the safety, efficacy and pharmacovigilance part of	10/06/22
	the dossier: Introduction of a summary of the PSMF or	
	changes to the summary of the PSMF not already covered	
	elsewhere in the Annex to Regulation (EU) 2021/17	